Details of the Drug Combinations

General Information of This Drug (ID: DMMX2E6)

Drug Name
Pemetrexed   DMMX2E6
Synonyms
Alimta; LYA; LY 231514; LY231514; Alimta (TN); LY 231,514; LY-2315; LY-231514; Pemetrexed (INN); Pemetrexed [INN:BAN]; LY-231,514; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
Indication
Disease Entry ICD 11 Status REF
Central nervous system lymphoma 2B33.5 Approved [1]
Epithelioid mesothelioma 2F10 Approved [1]
Lung cancer 2C25.0 Approved [1]
Malignant pleural mesothelioma 2C26.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [1]
Sarcomatoid mesothelioma N.A. Approved [1]
Small-cell lung cancer 2C25.Y Approved [1]
Lung neoplasm N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

46 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Al3818 + Pemetrexed DCN7DHO Al3818 Non-squamous Non-small Cell Lung Cancer [3]
Aminooxyacetic acid + Pemetrexed DC8M2IK Aminooxyacetic acid Advanced Malignant Solid Neoplasm [4]
Arfolitixorin + Pemetrexed DC9VZIB Arfolitixorin Rectal Cancer [5]
Cabozantinib + Pemetrexed DC4EQRP Cabozantinib Non Small Cell Lung Cancer [6]
Carboplatin + Pemetrexed DC94KAF Carboplatin Ovarian Cancer [7]
Carboplatin + Pemetrexed DCG6UKN Carboplatin Mesothelioma [8]
Carboplatin + Pemetrexed DC7Y2MG Carboplatin Non-small Cell Lung Carcinoma [9]
Dexamethasone + Pemetrexed DC520RD Dexamethasone Non Small Cell Lung Cancer [10]
Docetaxel + Pemetrexed DC4YXHW Docetaxel Breast Cancer [11]
Docetaxel + Pemetrexed DC7M6MW Docetaxel Lung Cancer [12]
Docetaxel + Pemetrexed DCBWDP3 Docetaxel Non Small Cell Lung Cancer [13]
Enzastaurin + Pemetrexed DC5PC5N Enzastaurin Non-small Cell Lung Cancer [14]
Erlotinib + Pemetrexed DC0OGCP Erlotinib Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. [15]
Erlotinib + Pemetrexed DCGQLKX Erlotinib Lung Cancer [16]
Erlotinib + Pemetrexed DCTG9PO Erlotinib Non-Small-Cell Lung Cancer [17]
Everolimus + Pemetrexed DC8UB8F Everolimus Non Small Cell Lung Cancer [18]
Gefitinib + Pemetrexed DC32TE0 Gefitinib Carcinoma, Non Small Cell Lung [19]
Gemcitabine + Pemetrexed DCFE26I Gemcitabine Breast Cancer [20]
Gemcitabine + Pemetrexed DCSFA8P Gemcitabine Lung Cancer [21]
Itraconazole + Pemetrexed DCRSO9C Itraconazole Recurrent Non Small Cell Lung Cancer [22]
Ixabepilone + Pemetrexed DC9XGP2 Ixabepilone Advanced Solid Tumors [23]
Lapatinib + Pemetrexed DCHUIOX Lapatinib Lung Cancer, Non-Small Cell [24]
LY2603618 + Pemetrexed DC03405 LY2603618 Non Small Cell Lung Cancer [25]
LY2606368 + Pemetrexed DCRTKMR LY2606368 Neoplasm Metastasis [26]
LY2835219 + Pemetrexed DCZXWWR LY2835219 Carcinoma, Non-small Cell Lung [27]
Panobinostat + Pemetrexed DC8YS6Z Panobinostat Non-Small Cell Lung Cancer [28]
Pazopanib + Pemetrexed DC0DM1I Pazopanib Lung Cancer, Non-Small Cell [29]
Pemetrexed + VATALANIB DC2RAD4 VATALANIB Unspecified Adult Solid Tumor, Protocol Specific [30]
Pemetrexed + Temsirolimus DC7KUDQ Temsirolimus Carcinoma, Non-Small-Cell Lung [31]
Pemetrexed + Oxaliplatin DCHGZZ8 Oxaliplatin Lung Cancer [32]
Pemetrexed + Vandetanib DCIIQRJ Vandetanib Non Small Cell Lung Cancer [33]
Pemetrexed + Irinotecan DCKT34Z Irinotecan Metastatic Colorectal Cancer [34]
Pemetrexed + Oxaliplatin DCVMNXK Oxaliplatin Lymphoma [35]
Pemetrexed + Vinflunine DCWR70B Vinflunine Unspecified Adult Solid Tumor, Protocol Specific [36]
Pemetrexed + Vandetanib DCY7CA6 Vandetanib Carcinoma [37]
Pemetrexed + Bosutinib DCKCLGF Bosutinib Carcinoma, Non-Small-Cell Lung [38]
Ro 31-7453 + Pemetrexed DCFKZYS Ro 31-7453 Advanced Cancer [39]
Selumetinib + Pemetrexed DCYAKQU Selumetinib Non Small Cell Lung Cancer [40]
Tasisulam + Pemetrexed DCEU2TE Tasisulam Solid Tumors [41]
Temozolomide + Pemetrexed DC21N87 Temozolomide Colon cancer [42]
Trametinib + Pemetrexed DCTTELS Trametinib Cancer [43]
Zibotentan + Pemetrexed DCC8EAA Zibotentan Non Small Cell Lung Cancer [44]
Pemetrexed + Oxaliplatin DCOJZ0H Oxaliplatin Esophagogastric Cancer [45]
Rivoceranib + Pemetrexed DCKV6KJ Rivoceranib Advanced Non-squamous Non-small-cell Lung Cancer [46]
Zanubrutinib + Pemetrexed DCMYC9O Zanubrutinib Primary Central Nervous System Lymphoma [47]
Gefitinib + Pemetrexed DC2J8AA Gefitinib Lung Neoplasms [48]
------------------------------------------------------------------------------------
⏷ Show the Full List of 46 DrugCom(s)

References

1 Pemetrexed FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6837).
3 ClinicalTrials.gov (NCT03566576) Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
4 ClinicalTrials.gov (NCT02535312) Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
5 ClinicalTrials.gov (NCT01397305) An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer
6 ClinicalTrials.gov (NCT04173338) Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
7 ClinicalTrials.gov (NCT00230542) Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
8 ClinicalTrials.gov (NCT00101283) Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
9 ClinicalTrials.gov (NCT02039674) A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
10 ClinicalTrials.gov (NCT00609518) A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
11 ClinicalTrials.gov (NCT01172028) Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
12 ClinicalTrials.gov (NCT00660816) Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
13 ClinicalTrials.gov (NCT00684099) Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)
14 ClinicalTrials.gov (NCT00530621) Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
15 ClinicalTrials.gov (NCT00447057) Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
16 ClinicalTrials.gov (NCT00387322) Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
17 ClinicalTrials.gov (NCT00550173) A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
18 ClinicalTrials.gov (NCT00434174) Safety of Everolimus and Pemetrexed in Lung Cancer Patients
19 ClinicalTrials.gov (NCT01469000) A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
20 ClinicalTrials.gov (NCT00063570) Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy
21 ClinicalTrials.gov (NCT00193414) Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
22 ClinicalTrials.gov (NCT00769600) Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC
23 ClinicalTrials.gov (NCT01170871) Ixabepilone and Pemetrexed/Solid Tumors
24 ClinicalTrials.gov (NCT00528281) A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
25 ClinicalTrials.gov (NCT00988858) A Study of Advanced or Metastatic Non-small Cell Lung Cancer
26 ClinicalTrials.gov (NCT02124148) A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
27 ClinicalTrials.gov (NCT02079636) A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
28 ClinicalTrials.gov (NCT00907179) Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
29 ClinicalTrials.gov (NCT00619424) A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
30 ClinicalTrials.gov (NCT00390000) Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
31 ClinicalTrials.gov (NCT00921310) Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
32 ClinicalTrials.gov (NCT00612677) Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
33 ClinicalTrials.gov (NCT00418886) Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
34 ClinicalTrials.gov (NCT00191984) A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer
35 ClinicalTrials.gov (NCT00470405) Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma
36 ClinicalTrials.gov (NCT00320073) Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors
37 ClinicalTrials.gov (NCT00506051) ZD6474(Vandetanib) + Alimta Combo Study
38 ClinicalTrials.gov (NCT03023319) Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
39 ClinicalTrials.gov (NCT00408226) Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
40 ClinicalTrials.gov (NCT01783197) Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
41 ClinicalTrials.gov (NCT01215916) A Phase 1 Study in Patients With Solid Tumors
42 ClinicalTrials.gov (NCT01985451) Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma PCNSL?Unknown status
43 ClinicalTrials.gov (NCT01192165) Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
44 ClinicalTrials.gov (NCT00745875) ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
45 ClinicalTrials.gov (NCT02296671) Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
46 ClinicalTrials.gov (NCT03190239) Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients
47 ClinicalTrials.gov (NCT05681195) Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
48 ClinicalTrials.gov (NCT02518802) Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma